Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck Applies for Covid Pill Approval in Japan, Nikkei Reports

12/03/2021 | 02:01am EST

--Merck & Co.'s Japan unit applied for approval of its Covid-19 pill in the country, local business daily Nikkei reported Friday, citing unnamed sources.

--If approved by the government, Merck plans to distribute the pill in Japan as early as later this month, the Nikkei report said.

Full story: https://s.nikkei.com/3DjwETO (Japanese)

Write to Kosaku Narioka at kosaku.narioka@wsj.com

(END) Dow Jones Newswires

12-03-21 0201ET

All news about MERCK & CO., INC.
02:15pMerck & Co. Declares Q2 Dividend of $0.69, Payable April 7 to Shareholders of Record Ma..
MT
01:35pMerck Announces Second-Quarter 2022 Dividend
BU
01/24Britain to Start Testing Merck & Co.'s COVID-19 Antiviral Drug
MT
01/24Egypt Clears Merck & Co.'s COVID-19 Pill For Emergency Use
MT
01/24EU Drug Regulator Reportedly Will Decide on Approval of Pfizer's COVID-19 Pill by End o..
MT
01/24US FDA Declines Approval For Merck &Co.'s New Cough Drug, Seeks Further Information
MT
01/24EU Medicines Watchdog to Issue Decision on Pfizer's COVID-19 Pill in January
MT
01/24FDA Declines to Approve Merck's Investigational Cough Treatment Gefapixant
MT
01/24MERCK : FDA Rejects Gefapixant Application, Requests More Data
DJ
01/24Merck Provides U.S. and Japan Regulatory Update for Gefapixant
BU
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 458 M - -
Net income 2021 11 938 M - -
Net Debt 2021 17 081 M - -
P/E ratio 2021 16,8x
Yield 2021 3,31%
Capitalization 199 B 199 B -
EV / Sales 2021 4,46x
EV / Sales 2022 3,73x
Nbr of Employees 73 500
Free-Float 70,6%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 78,83 $
Average target price 92,27 $
Spread / Average Target 17,1%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.2.86%199 120
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643
ELI LILLY AND COMPANY-12.00%217 963